Fulcrum Therapeutics (FULC) Accumulated Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Accumulated Expenses data on file, last reported at $5.0 million in Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $5.0 million, up 13.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.0 million (up 13.76% YoY), and the FY2025 annual result was $9.1 million, up 17.65% from the prior year.
• Accumulated Expenses retreated to $5.0 million in Q1 2026 per FULC's latest filing, from $9.1 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.5 million in Q2 2022 and troughed at $2.3 million in Q1 2024.
• A 5-year average of $5.3 million and a median of $4.4 million in 2025 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses surged 532.35% in 2022, then plunged 67.84% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $4.2 million in 2022, then rose by 11.9% to $4.7 million in 2023, then jumped by 63.29% to $7.7 million in 2024, then rose by 17.65% to $9.1 million in 2025, then slumped by 45.28% to $5.0 million in 2026.
• Business Quant data shows FULC's Accumulated Expenses at $5.0 million in Q1 2026, $9.1 million in Q4 2025, and $2.8 million in Q3 2025.